End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
16 CNY | -0.81% | -6.32% | -5.99% |
Jan. 19 | Tasly Pharmaceutical Gets Nod to Trial Stem Cell Therapy | MT |
Dec. 29 | ShuYu Civilian Pharmacy Corp., Ltd. Scraps Plan to Buy Stake in Tasly Pharmaceutical's Two Units | CI |
Sales 2023 * | 9.19B 1.27B | Sales 2024 * | 9.94B 1.38B | Capitalization | 23.81B 3.29B |
---|---|---|---|---|---|
Net income 2023 * | 1.22B 168M | Net income 2024 * | 1.35B 187M | EV / Sales 2023 * | 2.39 x |
Net cash position 2023 * | 1.86B 257M | Net cash position 2024 * | 4.35B 601M | EV / Sales 2024 * | 1.96 x |
P/E ratio 2023 * |
19.8
x | P/E ratio 2024 * |
17.8
x | Employees | 9,183 |
Yield 2023 * |
1.63% | Yield 2024 * |
1.4% | Free-Float | 49.13% |
1 day | -0.81% | ||
1 week | -6.32% | ||
Current month | -5.16% | ||
1 month | -2.91% | ||
3 months | -6.16% | ||
6 months | +13.39% | ||
Current year | -5.99% |
Managers | Title | Age | Since |
---|---|---|---|
Jing Su
CEO | Chief Executive Officer | 61 | 18-04-15 |
Jie Wei
DFI | Director of Finance/CFO | 47 | 18-07-08 |
Ying Zhao
IRC | Investor Relations Contact | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Xiao Meng Jiang
BRD | Director/Board Member | 60 | 07-08-16 |
Nai Feng Wu
BRD | Director/Board Member | 72 | 05-09-08 |
Kai Jing Yan
CHM | Chairman | 45 | 14-03-27 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 36 M€ | +4.74% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-27 | 16 | -0.81% | 10,753,000 |
24-03-26 | 16.13 | 0.00% | 11,370,680 |
24-03-25 | 16.13 | -1.77% | 13,151,300 |
24-03-22 | 16.42 | -1.85% | 14,267,910 |
24-03-21 | 16.73 | -2.05% | 13,664,980 |
End-of-day quote Shanghai S.E., March 26, 2024
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.99% | 3.29B | |
+22.71% | 5.39B | |
-12.40% | 4.67B | |
-17.15% | 2.6B | |
-3.06% | 2.52B | |
-6.78% | 1.7B | |
-8.49% | 1.61B | |
+22.27% | 1.63B | |
-5.38% | 1.56B | |
-9.25% | 1.41B |